Diabetes, Obesity & Metabolism

Fatty Liver Index and Differential Glycemic Responses to Ipragliflozin Versus Sitagliptin Over 52 Weeks: An Exploratory Post Hoc Analysis of the Niigata Ipragliflozin and Sitagliptin With Metformin (N-ISM) Study

By Masaru Kitazawa, Takashi Katagiri, Hiromi Suzuki, Hirohito Sone

Trial in peopleInterventions

The paper

Masaru Kitazawa, Takashi Katagiri, Hiromi Suzuki, Hirohito Sone

Niigata University

Diabetes, Obesity & Metabolism, 17 Aug 2026

doi.org/10.1111/dom.71211 PubMed 42605497

Diabetes & Vascular Disease Research4 Oct 2026
SGLT2 inhibitors link to lower dementia risk than GLP-1 drugs
Clinical Pharmacology and Therapeutics4 Oct 2026
SGLT2 inhibitors raise genital but not urinary infection risk
Diabetes, Obesity & Metabolism4 Oct 2026
GLP-1 drugs added to SGLT2 inhibitors linked to lower kidney risk